U01 Immune-Related Adverse Events Projects



As new components of the Immuno-Oncology Translation Network (IOTN), the overarching goal of these cancer immunotherapy research projects is to generate improved cancer immunotherapies that reduce the incidence and/or severity of immune-related adverse events (irAEs) while retaining anti-tumor efficacy.

Lead by single investigators and/or multidisciplinary teams with expertise in mechanisms of cancer immunology, immune tolerance, irAEs, autoimmunity, and/or patient characterization and selection, the specific objectives are to generate new ideas and approaches to better understand and thereby reduce the incidence and/or severity of irAEs resulting from cancer immunotherapy.